Prognostic factors for a composite end-point of renal outcomes in patients with chronic kidney disease

Therapeutic Apheresis and Dialysis

Volumn 10, Issue 1, 2006, Pages 72-77

  Morita, Satoshi ^a   Fukuhara, Shunichi ^a   Akizawa, Tadao ^b   Asano, Yasushi ^c   Koshikawa, Shozo ^d   Koide, Keizo ^e   Kurokawa, Kiyoshi ^f  

^a KYOTO UNIVERSITY   (Japan)

^b WAKAYAMA MEDICAL UNIVERSITY   (Japan)

^c JICHI MEDICAL UNIVERSITY   (Japan)

^d SHOWA UNIVERSITY FUJIGAOKA HOSPITAL   (Japan)

^e Tonan Hospital   (Japan)

^f UNIVERSITY OF TOKYO   (Japan)

Author keywords

Chronic kidney disease; Composite end point; Prognostic factor

Indexed keywords

CALCIUM CHANNEL BLOCKING AGENT; CREATININE; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR;

ADULT; AGE DISTRIBUTION; AGED; ANEMIA; ARTICLE; CHRONIC KIDNEY DISEASE; COHORT ANALYSIS; CONCENTRATION (PARAMETERS); CONTROLLED STUDY; CREATININE BLOOD LEVEL; DIABETIC NEPHROPATHY; DIALYSIS; DIET; DISEASE COURSE; FEMALE; GLOMERULONEPHRITIS; HEALTH STATUS; HUMAN; HYPERLIPIDEMIA; HYPERTENSION; INCIDENCE; JAPAN; KIDNEY TRANSPLANTATION; LOG RANK TEST; MAJOR CLINICAL STUDY; MALE; MULTIVARIATE ANALYSIS; NEPHROSCLEROSIS; PATHOGENESIS; PRIORITY JOURNAL; PROGNOSIS; PROPORTIONAL HAZARDS MODEL; PROSPECTIVE STUDY; SEX DIFFERENCE; UNIVARIATE ANALYSIS;

AGED; CALCIUM CHANNEL BLOCKERS; CREATININE; DIABETIC NEPHROPATHIES; DISEASE PROGRESSION; FEMALE; GLOMERULONEPHRITIS; HUMANS; KIDNEY FAILURE, CHRONIC; MALE; MIDDLE AGED; NEPHROSCLEROSIS; PROGNOSIS; PROSPECTIVE STUDIES;

EID: 33644982334     PISSN: 17449979     EISSN: 17449987     Source Type: Journal    
DOI: 10.1111/j.1744-9987.2006.00307.x     Document Type: Article

References (21)

1. The ICH Steering Committee. International Conference on Harmonization (ICH) of Technical Requirements for Registration of Pharmaceuticals for Human Use. ICH harmonized tripartite guideline: statistical principles for clinical trials. 1998
2. Brenner BM Cooper ME de Zeeuw D et al. Effects of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy N Engl J Med 2001 345 861 9
3. Lewis EJ Hunsicker LG Clarke WR et al. Renoprotective effect of the angiotensin-receptor blocker irbesartan in patients with nephropathy due to type-2 diabetes N Engl J Med 2001 345 851 60
4. Nakao N Noshimura A Morita H Takada M Kayano T Ideura T Combination treatment of angiotensin-II receptor blocker and angiotensin-converting enzyme-inhibitor in non-diabetic renal disease (COOPERATE): a randomised controlled trial Lancet 2003 361 117 24
5. Scott NW McPherson GC Ramsay CR Campbell MK The method of minimization for allocation to clinical trials: a review Control Clin Trials 2002 23 662 74
6. Keane WF Brenner BM de Zeeuw D et al. The risk of developing end-stage renal disease in patients with type 2 diabetes and nephropathy: the RENAAL study Kidney Int 2003 63 1499 507
7. Peterson JC Adler S Burkart JM et al. Blood pressure control, proteinuria, and the progression of renal disease. The Modification of Diet in Renal Disease Study Ann Intern Med 1995 123 754 62
8. Hunsicker LG Adler S Caggiula A et al. Predictors of the progression of renal disease in the Modification of Diet in Renal Disease Study Kidney Int 1997 51 1908 19
9. Breyer JA Bain RP Evans JK et al. Predictors of the progression of renal insufficiency in patients with insulin-dependent diabetes and overt diabetic nephropathy. The Collaborative Study Group Kidney Int 1996 50 1651 8
10. Hovind P Rossing P Tarnow L Smidt UM Parving HH Progression of diabetic nephropathy Kidney Int 2001 59 702 9
11. Ruggenenti P Perna A Gherardi G Benini R Remuzzi G Chronic proteinuric nephropathies. outcomes and response to treatment in a prospective cohort of 352 patients with different patterns of renal injury Am J Kidney Dis 2000 35 1155 65
12. Akizawa T Koide K Koshikawa S Effects of KREMEZIN on patients with chronic renal failure: Results of a nation-wide clinical study Kidney Dialysis 1998 45 373 88
13. Sanaka T Akizawa T Koide K Koshikawa S Protective effect of an oral adsorbent on renal function in chronic renal failure: determinants of its efficacy in diabetic nephropathy Ther Apher Dial 2004 8 232 40
14. Sanaka T Akizawa T Koide K Koshikawa S Clinical analysis of renoprotective responding patients administrated with oral adsorbent in chronic renal failure secondary to chronic glomerulonephritis Ther Apher Dial 2003 7 269 78
15. Sanaka T Fujimoto K Niwayama J et al. Effect of combined treatment of oral sorbent with protein-restricted diet on change of reciprocal creatinine slope in patients with CRF Am J Kidney Dis 2003 41 S35 7
16. Yorioka N Ito T Masaki T et al. Dose-dependent effect of an oral adsorbent, AST-120, in patients with early chronic renal failure J Int Med Res 2002 30 467 75
17. Sakamoto J Koike A Saji S Teramukai S Ohashi Y Nakazato H Preoperative serum immunosuppressive acidic protein (IAP) test for the prognosis of gastric cancer: a statistical study of the threshold level and evaluation of the effect of the biological response modifier PSK Jpn J Surg 1992 22 530 6
18. Cox DR Oakes D Analysis of Survival Data London Chapman & Hall 1984
19. Kaplan EL Meier P Nonparametric estimation form incomplete observations J Am Stat Assoc 1958 53 457 81
20. Maschio G Alberti D Janin G et al. Effect of the angiotensin-converting- enzyme inhibitor benazepril on the progression of chronic renal insufficiency. The Angiotensin-Converting-Enzyme Inhibition in Progressive Renal Insufficiency Research Group N Engl J Med 1996 334 939 45
21. Morita S Fukuhara S Akizawa T Asano Y Kurokawa K Study Design and Methods for a Clinical Trial for an Oral Carbonaceous Adsorbent Used to Prevent the Progression of Chronic Kidney Disease (CAP-KD) Clin Exp Nephrol 2005 9 217 27